HomeProductsBuilding BlocksHeterocyclic ScaffoldsQuinolinesTasquinimod
Chemical structure of CAS 254964-60-8

Tasquinimod

In Stock•Starting at $64 for 10 mg•Purity ≥ 98%
CAS No.254964-60-8
MDL No.MFCD18251454
MFC20H17F3N2O4
MW406.40
InChI KeyONDYALNGTUAJDX-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
10 mg98%$64In Stock
25 mg98%$126In Stock
50 mg98%$212In Stock
100 mg98%$358In Stock
250 mg98%$676In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

Tasquinimod is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic properties. It reduces blood vessel density, though its mechanism of action is unknown. Tasquinimod enhances the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer using human prostate cancer xenografts.

CAS No.254964-60-8
Product NameTasquinimod

Associated Conditions

multiple myeloma·prostate carcinoma·prostate cancer·metastatic prostate cancer·prostate adenocarcinoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.

The Prostate • Vol. 72, Issue 6 • 2012
PMID: 21837778PMC: PMC4086682DOI: 10.1002/pros.21467

Emerging treatment options for patients with castration-resistant prostate cancer.

The Prostate • Vol. 72, Issue 3 • 2012
PMID: 21748753DOI: 10.1002/pros.21435

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 29, Issue 30 • 2011
PMID: 21931019DOI: 10.1200/JCO.2011.35.6295

Bioanalysis in clinical development of tasquinimod using liquid chromatography/tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences • Vol. 879, Issue 30 • 2011
PMID: 21963277DOI: 10.1016/j.jchromb.2011.09.013

Documentation

Similar Products